Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles

Journal of Biomedical Materials Research

Volumn 35, Issue 4, 1997, Pages 525-530

  Cleek, Robert L ^a   Rege, Ajay A ^b   Denner, Larry A ^b   Eskin, Suzanne G ^b   Mikos, Antonios G ^a  

^a Rice University   (United States)

^b TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOSITION EFFECTS; MUSCLE; ORGANIC POLYMERS; PARTICLES (PARTICULATE MATTER); RNA; SOLVENT EXTRACTION;

CELL MIGRATION; CELL PROLIFERATION; MICROPARTICLES; OLIGODEOXYNUCLEOTIDE; SMOOTH MUSCLE CELLS (SMC);

CELLS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; POLYGLACTIN; TENASCIN;

ANIMAL CELL; ANIMAL TISSUE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; GROWTH INHIBITION; NONHUMAN; PARTICLE SIZE; RAT; RNA ANALYSIS; SMOOTH MUSCLE FIBER;

NON-PROGRAMMATIC;

ANIMALS; CELL DIVISION; CELL MOVEMENT; DRUG CARRIERS; MICROSPHERES; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TENASCIN;

EID: 8244225188     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4636(19970615)35:4<525::AID-JBM12>3.0.CO;2-A     Document Type: Conference Paper

References (31)

1. R. Ross, "The pathogenesis of atherosclerosis: A perspective for the 1990s," Nature, 362, 801-809 (1993).
2. K. J. Beatt, P. W. Serruys, and P. G. Hugenholtz, "Restenosis after coronary angioplasty: New standards for clinical studies," J. Am. Coll. Cardiol., 15, 491-498 (1990).
3. A. M. Lincoff, J. G. Furst, S. G. Ellis, and E. J. Topol, "Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery," J. Am. Coll. Cardiol., 23, 18A. Abstract (1994).
4. B. Goldman, H. Blanke, and H. Wolinsky, "Influence of pressure on permeability of normal and diseased arteries to horseradish peroxidase," Atherosclerosis, 65, 215-225 (1987).
5. H. Wolinsky and S. N. Thung, "Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the canine artery," J. Am. Coll. Cardiol., 15, 475-481 (1990).
6. E. R. Edelman, D. H. Adams, and M. J. Karnovsky, "Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury," Proc. Natl. Acad. Sci. USA, 87, 3773-3777 (1990).
7. A. E. Villa, L. A. Guzman, W. Chen, G. Golomb, R. J. Levy, and E. J. Topol, "Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty," J. Clin. Invest., 93, 1243-1249 (1994).
8. S. J. Holland, B. J. Tighe, and P. L. Gould, "Polymers for biodegradable medical devices. I. The potential of polyesters as controlled macromolecular release systems," J. Controlled Release, 4, 155-180 (1986).
9. A. M. Reed and D. K. Gilding, "Biodegradable polymers for use in surgery-poly(glycolic)/poly(lactic acid) homo and copolymers. II. In vitro degradation," Polymer, 22, 494-498 (1981).
10. Y. Shi, H. G. Hutchinson, D. J. Hall, and A. Zalewski, "Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells," Circulation, 88, 1190-1195 (1993).
11. S. Biro, Y. Fu, Z. Yu, and S. E. Epstein, "Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration," Proc. Natl. Acad. Sci. USA, 90, 654-658 (1993).
12. M. R. Bennett, S. Anglin, J. R. McEwan, R. Jagoe, A. C. Newby, and G. I. Evan, "Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides," J. Clin. Invest., 93, 820-828 (1994).
13. M. Simons, E. R. Edelman, J. L. DeKeyser, R. Langer, and R. D. Rosenberg, "Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo," Nature, 359, 67-70 (1992).
14. T. L. Burgess, E. F. Fisher, S. L. Ross, J. V. Bready, Y. X. Qian, L. A. Bayewitch, A. M. Cohen, C. J. Herrera, S. S. Hu, and T. B. Kramer, "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism," Proc. Natl. Acad. Sci. USA 92, 4051-4055 (1995).
15. Y. Shi, A. Fard, A. Galeo, H. G. Hutchinson, P. Vermani, G. R. Dodge, D. J. Hall, F. Shaheen, and A. Zalewski, "Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury," Circulation, 90, 944-951 (1994).
16. L. A. Denner, R. A. F. Dixon, S. G. Eskin, H. McAllister, A. A. Rege, D. L. Stacy, L. T. Sturgis, N. Kint, J. Tian, C. Munsch, C. Parnis, P. Capek, and J. T. Willerson, "Tenascin and fibroblast growth factor receptor 1 in restenosis," Circulation, 90, 1592 (1994).
17. E. J. Mackie, T. Scott-Burden, A. W. Hahn, F. Kern, J. Bernhardt, S. Regenass, A. Weller, and F. R. Buhler, "Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II," Am. J. Pathol., 142, 377-388 (1993).
18. U. Hedin, J. Holm, and G. K. Hansson, "Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype," Am. J. Pathol., 139, 649-656 (1991).
19. M. J. Alonso, R. K. Gupta, C. Min, G. R. Siber, and R. Langer, "Biodegradable microspheres as controlled-release tetanus toxoid delivery systems," Vaccine, 12, 299-306 (1994).
20. J. H. Chamley-Campbell, G. R. Campbell, and R. Ross, "Phenotype-dependent response to cultured aortic smooth muscle to serum mitogens," J. Cell Biol., 89, 379-383 (1981).
21. S. L. Ishaug, R. G. Payne, M. J. Yaszemski, T. B. Aufdemorte, R. Bizios, and A. G. Mikos, "Osteoblast migration on poly(α-hydroxy esters)," Biotech. Bioeng., 50, 443-451 (1996).
22. C. Yan, J. H. Resau, J. Hewetson, M. West, W. L. Rill, and M. Kende, "Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by water-in-oil-in-water emulsion technique," J. Controlled Release, 32, 231-241 (1994).
23. S. Cohen, T. Yoshioka, M. Lucarelli, L. H. Hwang, and R. Langer, "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharm. Res., 8, 713-720 (1991).
24. L. M. Sanders, B. A. Kell, G. I. McRae, and G. W. Whitehead, "Prolonged controlled release of narfarelin from biodegradable polymeric implants: Influence of composite and molecular weight of polymer," J. Pharm. Sci., 75, 356-360 (1986).
25. M. Iwata and J. W. McGinity, "Dissolution, stability, and morphological properties of conventional multiphase poly(DL-lactic-co-glycolic acid) microspheres containing water-soluble compounds," Pharm. Res., 10, 1219-1227 (1993).
26. E. R. Edelman and M. J. Karnovsky, "Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis," Circulation, 89, 770-776 (1994).
27. E. R. Edelman, M. Simons, M. G. Sirois, and R. D. Rosenberg, "C-myc in vasculoproliferative disease," Circ. Res., 76, 176-182 (1995).
28. J. Abe, W. Zhou, J. Taguchi, N. Takuwa, K. Miki, H. Okazaki, K. Kurokawa, M. Kumada, and Y. Takuwa, "Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery," Biochem. Biophys. Res. Commun., 198, 16-24 (1994).
29. C. A. Stein and Y. C. Cheng, "Antisense oligonucleotides as therapeutic agents - is the bullet really magical?," Science, 261, 1004-1012 (1993).
30. M. A. Guvakova, L. A. Yakubov, I. Vlodavsky, J. L. Tonkinson, and C. A. Stein, "Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix," J. Biol. Chem., 270, 2620-2627 (1995).
31. W. Y. Gao, F. S. Han, C. Storm, W. Egan, and Y. C. Ceng, "Phosphorothioate Oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology," Mol. Pharm., 41, 223-229 (1992).